AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10530259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivisit treatment with calcium hydroxide
Number of subjects: 3
Study 10530259 — intervention group
Group type: COMPARATOR
Intervention: Multivisit treatment without calcium hydroxide
Number of subjects: 3
Study 8821109 — intervention group
Group type: EXPERIMENTAL
Intervention: Shielded 3 ml safety syringe and components of a needleless IV system
Number of subjects: 47
Study 2149543 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol-sobrerol combination
Number of subjects: 287
Study 2149543 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol alone
Number of subjects: 287
Study 7362451 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 treatment (200 micrograms/day)
Number of subjects: 15
Study 7362451 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 15
Study 7362451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 31131635 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking campaign exposure (Give me one lung cancer campaign)
Number of subjects: 207
Study 30150326 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic app
Number of subjects: 163
Study 30150326 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced app
Number of subjects: 163
Study 30150326 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 163
Study 28916975 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation (1000 mg n‐3 fatty acid containing 400 mg α‐Linolenic acid)
Number of subjects: 60
Study 28916975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25662205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax laryngoscope
Number of subjects: 141
Study 25662205 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview laryngoscope
Number of subjects: 141
Study 25662205 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope laryngoscope
Number of subjects: 141
Study 25662205 — intervention group
Group type: COMPARATOR
Intervention: Miller laryngoscope
Number of subjects: 141
Study 23638784 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive MCS (ankle pressure: 8‐12 mmHg; calf pressure: 21‐25 mmHg)
Number of subjects: 220
Study 23638784 — intervention group
Group type: COMPARATOR
Intervention: Degressive MCS (ankle pressure: 24‐28 mmHg; calf pressure: 14‐18 mmHg)
Number of subjects: 220
Study 21174486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone (5 mg)
Number of subjects: 41
Study 19515734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g EPA+DHA/d
Number of subjects: 111
Study 19515734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g EPA+DHA/d
Number of subjects: 111
Study 19515734 — intervention group
Group type: COMPARATOR
Intervention: 4.0 g high-oleic acid sunflower oil (HOSF)/d
Number of subjects: 111
Study 17894535 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 0
Study 17894535 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine
Number of subjects: 0
Study 15234278 — intervention group
Group type: EXPERIMENTAL
Intervention: Super blue-green algae (SBGA) capsules
Number of subjects: 24
Study 15234278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11691500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive hypoglycemic regimen (diet modification plus troglitazone)
Number of subjects: 40
Study 11691500 — intervention group
Group type: COMPARATOR
Intervention: Conservative hypoglycemic regimen (diet modification plus placebo)
Number of subjects: 40
Study 11691500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (intensive and conservative)
Number of subjects: 40
Study 11691500 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without glycemic improvement
Number of subjects: 40
Study 11691500 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved glycemic control
Number of subjects: 40
Study 9405904 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline proinsulin levels
Number of subjects: 1193
Study 9405904 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, male sex, fasting and 2-h glucose levels
Number of subjects: 1193
Study 9405904 — intervention group
Group type: COMPARATOR
Intervention: Waist-to-hip ratio and BMI
Number of subjects: 1193
Study 9405904 — intervention group
Group type: COMPARATOR
Intervention: Incidence of NIDDM
Number of subjects: 1193
Study 7950208 — intervention group
Group type: EXPERIMENTAL
Intervention: Baoyuan Dahuang Decoction
Number of subjects: 56
Study 7950208 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive treatment of Western medicine (Control)
Number of subjects: 56
Study 3294888 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydiazyme (CZ)
Number of subjects: 1059
Study 3294888 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroTrak (MT)
Number of subjects: 1059
Study 3294888 — intervention group
Group type: COMPARATOR
Intervention: Culture system
Number of subjects: 1059
Study 2232019 — intervention group
Group type: EXPERIMENTAL
Intervention: Child and Parent Group
Number of subjects: 3
Study 2232019 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Group
Number of subjects: 3
Study 2232019 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific Control Group
Number of subjects: 3
Study 1094819 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral isosorbide dinitrate
Number of subjects: 18
Study 1094819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30721780 — intervention group
Group type: COMPARATOR
Intervention: Rigid instruments
Number of subjects: 16
Study 30721780 — intervention group
Group type: COMPARATOR
Intervention: da Vinci system
Number of subjects: 16
Study 30721780 — intervention group
Group type: EXPERIMENTAL
Intervention: Steerable instrument
Number of subjects: 16
Study 30721780 — intervention group
Group type: EXPERIMENTAL
Intervention: Steerable instruments
Number of subjects: 16
Study 28346472 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassuring information with a simple non‐threatening explanation for LBP (functional‐disturbance model)
Number of subjects: 505
Study 25813525 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 4 (Q4) of plasma 25(OH)D
Number of subjects: 548
Study 25813525 — intervention group
Group type: COMPARATOR
Intervention: Mean plasma 25(OH)D
Number of subjects: 548
Study 23579183 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied over the hand motor area
Number of subjects: 16
Study 23579183 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied over the leg motor area
Number of subjects: 16
Study 23579183 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 21273184 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-assisted computer-based (CAC) psychological treatment
Number of subjects: 97
Study 21273184 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention (BI)
Number of subjects: 97
Study 21273184 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered treatment
Number of subjects: 97
Study 19296875 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched yoghurt drink (2 g/d)
Number of subjects: 200
Study 19296875 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil n-3 LC-PUFA capsules (2 g/d)
Number of subjects: 200
Study 19296875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plant sterols and fish oil n-3 LC-PUFA
Number of subjects: 200
Study 19296875 — intervention group
Group type: COMPARATOR
Intervention: Control yoghurt drink and control capsules
Number of subjects: 200
Study 16500071 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychosocial support by specially trained oncology nurses (INS)
Number of subjects: 120
Study 16500071 — intervention group
Group type: COMPARATOR
Intervention: Individual psychosocial support by psychologists (IPS)
Number of subjects: 120
Study 15313950 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 199
Study 15313950 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 199
Study 15313950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 11557642 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) administration (17beta‐estradiol, transdermal patch, 0.1 mg/day)
Number of subjects: 12
Study 11557642 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) with P(4) administration (vaginal gel, 90 mg P(4) twice per day)
Number of subjects: 12
Study 11557642 — intervention group
Group type: COMPARATOR
Intervention: GnRH analog alone
Number of subjects: 12
Study 9370073 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 9370073 — intervention group
Group type: COMPARATOR
Intervention: No radiation therapy
Number of subjects: 0
Study 9370073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiation therapy
Number of subjects: 0
Study 8394956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate therapy
Number of subjects: 0
Study 8394956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8394956 — intervention group
Group type: EXPERIMENTAL
Intervention: AA meeting attendance
Number of subjects: 0
Study 3621549 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dermal anaesthesia (EMLA)
Number of subjects: 21
Study 31237242 — intervention group
Group type: EXPERIMENTAL
Intervention: iQuit Mindfully (MBAT + between-session text messages)
Number of subjects: 71
Study 31237242 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-Based Addiction Treatment (MBAT)
Number of subjects: 71
Study 28554988 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder (twice daily for 3 months)
Number of subjects: 0
Study 28554988 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (twice daily for 3 months)
Number of subjects: 0
Study 28554988 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder
Number of subjects: 0
Study 28554988 — intervention group
Group type: COMPARATOR
Intervention: Garlic powder and Placebo
Number of subjects: 0
Study 25453396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU daily)
Number of subjects: 104
Study 25453396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 23313040 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous peroneal (fibular) nerve stimulation neuroprosthesis for 3 months
Number of subjects: 10
Study 22019965 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal osteoporosis group
Number of subjects: 26
Study 22019965 — intervention group
Group type: COMPARATOR
Intervention: Nonosteoporotic control group
Number of subjects: 26
Study 18430848 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk
Number of subjects: 215
Study 18430848 — intervention group
Group type: COMPARATOR
Intervention: VoLumen
Number of subjects: 215
Study 16436459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed intervention consisting of a letter with psychological score feedback and a self-help sheet
Number of subjects: 233
Study 16436459 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 233
Study 12913036 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 5153
Study 12913036 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 5153
Study 12913036 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for BMI and resting heart rate (HR)
Number of subjects: 5153
Study 10473841 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluene (1.5 mg/min, 4 mg/min), Trichloroethylene (1.5 mg/min, 4 mg/min), n-Hexane (0.3 mg/min, 1.0 mg/min) administered via gastrointestinal application for 60 min.
Number of subjects: 8
Study 10473841 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluene, Trichloroethylene, n-Hexane exposure via gastrointestinal application.
Number of subjects: 8
Study 8595536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 494
Study 8595536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 15 mg
Number of subjects: 494
Study 8595536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 1928028 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐antibody positive cocaine addicts
Number of subjects: 44
Study 1928028 — intervention group
Group type: COMPARATOR
Intervention: HIV‐seronegative cocaine addicts
Number of subjects: 44
Study 6351590 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate
Number of subjects: 32
Study 6351590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29022755 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM zolmitriptan 3.8 mg
Number of subjects: 0
Study 29022755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26518044 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine targeting HPV-16 and HPV-18
Number of subjects: 0
Study 24118561 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary program for increasing self-efficacy
Number of subjects: 42
Study 24118561 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 22654512 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory exercises (GM)
Number of subjects: 46
Study 22654512 — intervention group
Group type: COMPARATOR
Intervention: Strength training (GS)
Number of subjects: 46
Study 20461002 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 200 microg
Number of subjects: 56
Study 20461002 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 400 microg
Number of subjects: 56
Study 20461002 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 25 microg
Number of subjects: 56
Study 20461002 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 100 microg
Number of subjects: 56
Study 20461002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18661867 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-unit polystyrene microparticles (50% indomethacin load)
Number of subjects: 0
Study 18661867 — intervention group
Group type: COMPARATOR
Intervention: Commercial Microcid immediate-release capsules
Number of subjects: 0
Study 18661867 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized microparticles
Number of subjects: 0
Study 18661867 — intervention group
Group type: COMPARATOR
Intervention: Indocap-SR capsules
Number of subjects: 0
Study 16280946 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly receiving a free helmet in the ED
Number of subjects: 200
Study 16280946 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher intervention (receiving a voucher for a free helmet)
Number of subjects: 200
Study 16280946 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care with verbal counseling)
Number of subjects: 200
Study 12558777 — intervention group
Group type: EXPERIMENTAL
Intervention: B-domain deleted recombinant factor VIII (BDDrFVIII)
Number of subjects: 218
Study 9459225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine bolus (1.5 mg/kg) and infusion (3 mg/min, unless weight <70 kg, then 2 mg/min)
Number of subjects: 40
Study 9459225 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 40
Study 8546286 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway in the Trendelenburg position
Number of subjects: 90
Study 8546286 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway in the lithotomy position
Number of subjects: 90
Study 8546286 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway in the supine position
Number of subjects: 90
Study 2403850 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine 0.15 mg.kg‐1
Number of subjects: 20
Study 2403850 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine 0.25 mg.kg‐1
Number of subjects: 20
Study 2403850 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine 0.50 mg.kg‐1
Number of subjects: 20
Study 2403850 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine 1.00 mg.kg‐1
Number of subjects: 20
Study 2403850 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine (various doses)
Number of subjects: 20
Study 2403850 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine
Number of subjects: 20
Study 734314 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin, 100 mg orally
Number of subjects: 24
Study 734314 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone, 5 mg
Number of subjects: 24
Study 31031072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior need for advanced techniques (ultrasound guidance or external jugular vein catheterization)
Number of subjects: 600
Study 31031072 — intervention group
Group type: COMPARATOR
Intervention: No prior difficulty
Number of subjects: 600
Study 26797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydronidone 15-120 mg single dose
Number of subjects: 88
Study 26797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydronidone 90 and 120 mg thrice daily for 7 days
Number of subjects: 88
Study 26797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydronidone 60 mg thrice daily for 28 days
Number of subjects: 88
Study 26797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydronidone with food
Number of subjects: 88
Study 26797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydronidone (all doses)
Number of subjects: 88
Study 25385061 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.4% (Acular LS, Allergan)
Number of subjects: 126
Study 25385061 — intervention group
Group type: EXPERIMENTAL
Intervention: nepafenac 0.1% (Nevanac, Alcon)
Number of subjects: 126
Study 25385061 — intervention group
Group type: COMPARATOR
Intervention: topical artificial tear substitute (placebo)
Number of subjects: 126
Study 23632035 — intervention group
Group type: EXPERIMENTAL
Intervention: Thylakoids added to a high carbohydrate meal
Number of subjects: 20
Study 23632035 — intervention group
Group type: COMPARATOR
Intervention: Control (high carbohydrate meal without thylakoids)
Number of subjects: 20
Study 21329821 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% EDTA
Number of subjects: 35
Study 21329821 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% citric acid
Number of subjects: 35
Study 21329821 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium citrate
Number of subjects: 35
Study 21329821 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% malic acid
Number of subjects: 35
Study 21329821 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acetic acid
Number of subjects: 35
Study 21329821 — intervention group
Group type: EXPERIMENTAL
Intervention: apple vinegar
Number of subjects: 35
Study 21329821 — intervention group
Group type: COMPARATOR
Intervention: Control (no irrigation)
Number of subjects: 35
Study 19470311 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Treatment group (7 clinic visits across 18 months)
Number of subjects: 108
Study 19470311 — intervention group
Group type: COMPARATOR
Intervention: Delayed Treatment group (9 clinic visits across 24 months)
Number of subjects: 108
Study 19470311 — intervention group
Group type: EXPERIMENTAL
Intervention: Late Completers (n=39)
Number of subjects: 108
Study 19470311 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawals
Number of subjects: 108
Study 17309139 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 136
Study 17309139 — intervention group
Group type: EXPERIMENTAL
Intervention: T-tube
Number of subjects: 136
Study 15570076 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (LV and FU plus oxaliplatin 85 mg/m2 IV over 2 hours on day 1)
Number of subjects: 214
Study 15570076 — intervention group
Group type: COMPARATOR
Intervention: LV5FU2 (LV 200 mg/m2 IV and FU 400 mg/m2 IV bolus, followed by FU 600 mg/m2 IV over 22 hours on days 1 and 2)
Number of subjects: 214
Study 15570076 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (among patients who crossed over from LV5FU2)
Number of subjects: 214
Study 15570076 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3/4 toxicities for FOLFOX4
Number of subjects: 214
Study 15570076 — intervention group
Group type: COMPARATOR
Intervention: Grade 3/4 toxicities for LV5FU2
Number of subjects: 214
Study 11234669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (175 anti‐Xa IU/kg) administered subcutaneously once daily for 10 days
Number of subjects: 30
Study 9087473 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (dose higher than 1 mg per day)
Number of subjects: 1602
Study 9087473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1602
Study 9087473 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 1602
Study 7655702 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular treatment with beta-agonists (unspecified dosage and duration)
Number of subjects: 0
Study 7655702 — intervention group
Group type: COMPARATOR
Intervention: As-needed beta-agonists (unspecified dosage and duration)
Number of subjects: 0
Study 7655702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (unspecified dosage)
Number of subjects: 0
Study 7655702 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (unspecified dosage)
Number of subjects: 0
Study 1972850 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg once a day
Number of subjects: 87
Study 1972850 — intervention group
Group type: COMPARATOR
Intervention: erythromycin 500 mg twice a day
Number of subjects: 87
Study 524621 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND)
Number of subjects: 0
Study 524621 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate (TE)
Number of subjects: 0
Study 31570258 — intervention group
Group type: EXPERIMENTAL
Intervention: ACURATE neo TAVR system
Number of subjects: 739
Study 31570258 — intervention group
Group type: COMPARATOR
Intervention: SAPIEN 3 TAVR system
Number of subjects: 739
Study 28702451 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization in prone (SIP)
Number of subjects: 56